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http://dx.doi.org/10.1016/j.jds.2012.0Abstract Studies have shown that topical 5-aminolevulinic acid-mediated photodynamic
therapy (ALA-PDT) can be used successfully for the treatment of oral verrucous hyperplasia
(OVH). Studies have also demonstrated that cryotherapy could be used as a treatment
modality for OVH lesions. In this case report, we tested the efficacy of topical ALA-PDT,
combined with cryogun cryotherapy, for an extensive OVH lesion on the right buccal mucosa
of a 65-year-old male areca quid chewer. The tumor was cleared after six treatments of
combined topical ALA-PDT and cryogun cryotherapy. No recurrence of the lesion was found
after a follow-up period of 18 months. We suggest that our combined treatment protocol
may be effective in treating OVH lesions. The treatment course may be slightly shortened with
this combined protocol and was well tolerated by the patient.
Copyright ª 2012, Association for Dental Sciences of the Republic of China. Published by
Elsevier Taiwan LLC. All rights reserved.Introduction
Oral verrucous hyperplasia (OVH) is a premalignant lesion
that may transform into a verrucous carcinoma orof Dentistry, Oral Medicine
sity Hospital, Number 110,
hung 40201, Taiwan.
u.tw (C.-H. Yu).
iation for Dental Sciences of the Re
9.024a squamous cell carcinoma.1 Traditional treatment for an
OVH is total surgical excision, which always leads to scar
formation for a large OVH lesion. Photodynamic therapy
(PDT) is another effective treatment option for human
premalignant and malignant lesions, because it is nonin-
vasive, is well tolerated by patients, can be used repeat-
edly without cumulative side effects, and results in little
scar formation.2 Studies have shown that topical 5-
aminolevulinic acid-mediated photodynamic therapy (ALA-
PDT) can be used successfully for the treatment of OVH.3e8public of China. Published by Elsevier Taiwan LLC. All rights reserved.
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as a treatment modality for OVH lesions.9,10 The advan-
tages of cryotherapy include bloodless treatment, a very
low incidence of secondary infection, and a relative lack of
scarring and pain.9
A previous study showed a successful treatment of an
extensive verrucous lesion with the topical ALA-PDT
protocol (with a fluence rate of 100 mW/cm2 and a light
exposure dose of 100 J/cm2) using a 635-nm light-emitting
diode (LED) light source. The verrucous lesion showed
complete regression after 28 treatments (6 treatments for
the extraoral portion and 22 treatments for the intraoral
portion) of this protocol.6 In this case report, we tested the
efficacy of the same topical ALA-PDT protocol, using a laser
light source combined with cryogun cryotherapy, for an
extensive OVH lesion on the right buccal mucosa of a 65-
year-old male areca quid chewer. We tested this
combined treatment protocol for OVH, to see if it would be
more effective than treatment with topical ALA-PDT alone.Case report
The patient is a 65-year-old male, who had a painless ver-
rucous lesion at the right buccal mucosa for 5 years. He
ignored it and did not seek any treatment until he felt it
became larger and interfered with eating, and wearing his
lower removable partial denture. He had an incisional
biopsy for the lesion at the oral and maxillofacial depart-
ment in a medical center, 2 weeks before he came to our
outpatient dental clinic. The histopathological report was
an atypical verrucous hyperplasia. He was advised to
undergo removal of the whole lesion by surgery, under
general anesthesia, but he refused because of his old age,
having hypertension and cardiovascular disease, and was
unwilling to receive any form of surgery. Therefore, his
daughter searched for an alternative treatment modality
for OVH from the Internet and found that ALA-PDT was
a non-invasive and an effective treatment option for OVH.
Thus, the patient, accompanied by his daughter, visited the
Department of Dentistry, Oral Medicine Center, Chung Shan
Medical University Hospital (CSMUH) and asked for treat-
ment of his OVH lesion by topical ALA-PDT.
The patient’s past medical history included a gallbladder
stone, which was treated by surgery 8 years previously. He
also had hypertension and myocardial infarction, which
were well controlled by medication. The patient had had
the areca quid chewing habit (20 quids/day) for 10 years
and had quit the habit for 12 years.
Extraoral examination showed no significant facial asym-
metry, or cervical lymphadenopathy. Intraoral examination
revealed an exophytic mass, with verrucous appearance,
which extended from the right buccal mucosa to the lower
labial mucosa (Fig. 1A). It measured approximately
4 2 1 cm3. Based on the size and appearance of the lesion,
the tentative clinical diagnosis was an oral verrucous carci-
noma. An incisional biopsy taken from the tumor portion near
the right mouth angle was performed. The histopathological
diagnosiswasa“verrucoushyperplasia” (Fig. 1B).Becauseonly
a small part of the tumor was examined histologically, we still
could not rule out the possibility of the concomitant presence
of an oral verrucous carcinoma in other parts of the lesion.The patient lived a distance from our hospital and
needed his family to bring him for treatment. Considering
the patient’s age and general health, the transportation
problem to our hospital, and the necessity of the family to
accompany him, we decided to treat this patient with
combined ALA-PDT and cryotherapy, to reduce the treat-
ment course, after informed consent was obtained from the
patient. This treatment protocol was reviewed and
approved by the Human Investigation Review Committee at
the CSMUH. The lesion was irradiated with a 635-nm laser
light (Arts-Laser, Arts International Biotechnology, Inc.,
Taipei, Taiwan) 1.5 hours after topical application of 20%
ALA onto the lesion, for a total of 1000 seconds (fluence
rate Z 100 mW/cm2, light exposure dose Z 100 J/cm2).
The 1000-second treatment period was divided into
five  3-minute and one  100-second irradiations, sepa-
rated by five  3-minute rests. Light treatments were
carried out under local anesthesia, using 2% lidocaine, with
the patient completely conscious. After ALA-PDT, cryogun
cryotherapy was performed onto the lesion. The lesion was
air-dried, and the surface was sprayed with liquid nitrogen
for 7e10 seconds, to form an ice field of the lesion. The
frozen field was then allowed to thaw for at least 20
seconds. Four or five consecutive freezeethaw cycles were
performed on the same lesion. During the liquid nitrogen
spray, the tip of the straight spray needle (model #107-16,
1.5 inches  16 g; Brymill Corp., Ellington, CT, USA) was
positioned 1 cm from the target site and at a 90 angle to it.
During the treatment procedure, high-power suction was
used to remove the saliva and vapor fog and to improve
visibility. Analgesics (acetaminophen, 500 mg/tablet, 1
tablet 4 times a day) were prescribed to the patient after
treatment. As stated by the patient, posttreatment pain
was mild and needed no analgesics. The tumor was cleared
after six treatments of combined ALA-PDT and cryogun
cryotherapy (Fig. 1CeE). The patient was then followed up
once a week for the first month and once every 3 months
thereafter. No recurrence of the lesion was found after
a follow-up period of 18 months (Fig. 1F).Discussion
In this case report, we treated a large OVH lesion on the
right buccal mucosa of a 65-year-old male areca quid
chewer, with a combined topical ALA-PDT and cryogun
cryotherapy protocol. The large OVH lesion showed
complete regression after six treatments with this
combined method. The results of the present report
revealed that topical ALA-PDT, combined with cryogun
cryotherapy, is very effective for treating a large OVH
lesion.
The clinical appearance and treatment course of this
OVH lesion were comparable to those of an OVC lesion re-
ported by Chen et al.4 Both lesions were extensive and
located on the right buccal mucosa. In their case, the
extraoral verrucous tumor at the right mouth angle
measured about 3  2.5  1 cm3. It was cleared after six
treatments of ALA-PDT, with a light exposure dose of 100 J/
cm2 at each treatment. In our case, the tumor measured
approximately 4  2  1 cm3, which was slightly larger than
that of their case. Although we used a laser light source for
Figure 1 Clinical and histopathological photographs of the patient. (A) The initial oral verrucous hyperplasia (OVH) lesion on the
right buccal mucosa before treatment. (B) Incisional biopsy of the tumor portion near the right mouth angle showing OVH
(hematoxylin and eosin stain; original magnification, 40). Clinical pictures of the OVH (C) after two treatments and (D) after four
treatments with topical 5-aminolevulinic acid photodynamic therapy (ALA-PDT) combined with cryogun cryotherapy, showing
partial regression of the OVH lesions. (E) Clinical picture of the OVH lesion showing complete regression after six treatments of the
combined treatment protocol. (F) Clinical picture of the patient showing no recurrence of the tumor after a follow-up period of 18
months.
Combined PDT and cryotherapy 89ALA-PDT instead of an LED light source, a previous study
disclosed that there is no significant difference in clinical
outcomes of oral erythroleukoplakia lesions treated with
PDT using either the LED or laser light.11 With the same light
exposure dose of ALA-PDT plus cryogun cryotherapy, our
case showed complete regression of the tumor after six
treatments, which was the same treatment number of the
case that was presented by Chen et al.4 In addition, there
were no significant clinical complications, like severe pain
or secondary infection, after this combined treatment
modality. Our patient needed no analgesics to control
posttreatment pain. These data suggest that ALA-PDT,
combined with cryogun cryotherapy, may slightly shorten
the treatment course and was well tolerated by the
patient.
The successful treatment, as well as a shorter treatment
course of our case, with topical ALA-PDT combined withcryogun cryotherapy, could be due to the synergistic
effects of mechanisms of ALA-PDT and cryotherapy. ALA
itself is not a photosensitizer, but serves as the biological
precursor of the photosensitizer, protoporphyrin IX (PpIX),
in the heme biosynthesis pathway. When ALA is topically
applied onto the lesion, it diffuses into epithelial cells and
is then metabolized into PpIX in the mitochondrial matrix
and cytosol. Treatment with a light of 635-nm wavelength,
can activate PpIX in lesional epithelial cells; PpIX, in turn,
transfers energy from light to molecular oxygen, resulting
in the generation of reactive oxygen species, to cause cell
damage and tumor destruction.4 Topical ALA-PDT is
a better treatment modality for oral precancers than
systemic ALA-PDT, because systemic administration of ALA
to patients has side effects of nausea, vomiting, and
elevation of blood levels of bilirubin and liver enzymes
(e.g., aspartate transaminase),12 while the direct local
90 Y.-C. Chang, C.-H. Yuapplication of ALA onto oral lesions produces none of those
systemic side effects.13e15 In addition, because topical
ALA-PDT for oral lesions uses only a small amount of ALA, it
causes no cutaneous photosensitivity, even with exposure
of the patient’s skin to the sun immediately after
treatment.
Most animal tissues freeze at 2.2C and cell death
occurs at a temperature of 20C.16 The mechanisms for
cell destruction after cryotherapy are complex, involving
a combination of direct and indirect effects.17 Direct
effects consist of ice crystals that form in both extracellular
and intracellular fluid, cellular dehydration, toxic intra-
cellular electrolyte concentration, inhibition of enzymes,
protein damage, thawing effects that cause cells to become
vacuolated, swell and rupture,17,18 and thermal shock
injury to cells.17 Indirect effects include vascular changes
that lead to ischemic necrosis of the treated tissue, and
immunological responses that cause cell damage through
cytotoxic immune mechanism.17,18
We used topical ALA-PDT followed by cryotherapy to
treat the OVH lesion, because efficient PDT needs sufficient
and a continuous supply of PpIX and oxygen. Our topical
ALA-PDT treatment protocol included six periods of light
treatment, which were interrupted by five periods of 3-
minute rest. Using this protocol, multiple 3-minute stops
were supposed to give the opportunities for tissues to
regenerate new PpIX and to obtain new oxygen. This, in
turn, resulted in a successful clinical outcome for OVH.
Cryotherapy was conducted after PDT, to enhance the
cytotoxic effects. This combined protocol may cause more
deleterious damage to cells, resulting in a shorter treat-
ment course.
The successful treatment with this combined method
may provide a new treatment modality for a large OVH
lesion. There are some advantages of this method. For such
a large lesion, traditional surgical intervention may cause
scar formation and restricted mouth opening. In addition,
the large surgical wound may be painful and has a chance of
secondary infection if the patient or the surgeon ignore
postoperative wound care. By our combined method,
however, no scar formation or restricted mouth opening
developed after treatment. The postoperative pain was
well-tolerated by the patient.
In this case report, we succeeded in treating a large OVH
with topical ALA-PDT combined with cryogun cryotherapy.
Although further studies are needed to verify the actual
efficacy of this treatment method, we suggest that our
combined treatment protocol may be effective in treating
OVH lesions. The treatment course may be slightly short-
ened with this combined protocol and was well tolerated by
the patient.
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